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 Folate Receptor Autoimmunity and Cerebral 
Folate Deﬁ ciency in Low-Functioning Autism with 
Neurological Deﬁ cits 
belief is that primary autism is caused by the 
impact of unidentiﬁ ed environmental factors in a 
genetically predisposed child  [12] . 
 We have previously reported that folate trans-
port to the CNS is reduced in a number of chil-
dren suffering from two autism spectrum 
disorders, i.e., Rett syndrome and infantile-onset 
low-functioning autism  [13 – 5] . Among 28 
patients affected by the infantile-onset cerebral 
folate deﬁ ciency (CFD) syndrome, 5 patients 
were found to manifest low-functioning autism 
with neurological deﬁ cits  [15] . In 4 of these 5 
autistic patients with low 5MTHF in their cere-
brospinal ﬂ uid (CSF), the aetiology was attributed 
to circulating autoantibodies in their serum 
directed against the folate receptors (FR). In 
patients with CFD these FR autoantibodies bind 
to the FR expressed on the choroid plexus and 
block the folate binding site, thereby inhibiting 
the transport of folate into the CSF  [15] . 
 Thus, FR autoimmunity and CFD appear to be 
common factors that play a crucial role in the 
cause and pathogenesis of autism spectrum dis-
orders or in a particular subgroup of the autism 
spectrum with co-existing neurological deﬁ cits. 
 Introduction 
 & 
 Autism is deﬁ ned as a behavioural syndrome of 
early childhood, which can be divided into ﬁ ve 
clinical subtypes, i.e., early infantile low-func-
tioning autism (Kanner syndrome), high-func-
tioning autism (Asperger syndrome), 
disintegrative disorder (Heller syndrome), Rett 
syndrome and atypical autism (PDD-NOS)  [5,  9] . 
These autism syndromes share impaired func-
tions involving sociability, language, non-verbal 
communicative skills, and imagination, together 
with narrow, rigid, and perseverative interests 
and activities. Autism is regularly associated with 
neurological deﬁ cits including stereotypy, difﬁ -
culties with posture, gait and balance, hypotonia, 
toe walking, clumsiness, dyspraxia, as well as 
disorders of sleep and attention, language disor-
ders and cognitive deﬁ cits. By adulthood a third 
of the individuals with the autistic spectrum dis-
order will have had at least two unprovoked epi-
leptic seizures  [1,  6,  16] . Autism with no evident 
cause, so-called primary autism, represents the 
major group, whereas secondary autism is 
responsible for 10 – 0  % of all cases. The general 
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 Abstract 
 & 
 Reduced folate transport to the CNS was identi-
ﬁ ed in two autism spectrum disorders, i.e., Rett 
syndrome and infantile low-functioning autism 
with neurological abnormalities. Twenty-ﬁ ve 
patients with early-onset low-functioning autism 
with or without neurological deﬁ cits, were 
evaluated for serum folate, cerebrospinal ﬂ uid 
(CSF) 5-methyltetrahydrofolate (5MTHF), and 
serum FR autoantibodies of the blocking type to 
determine the signiﬁ cance of folate receptor (FR) 
autoantibodies with respect to folate transport 
across the blood-CSF barrier. In spite of normal 
serum folate, CSF 5MTHF was low in 23 of 25 
patients. The reduced CSF folate in 19 of these 23 
patients could be explained by serum FR autoan-
tibodies blocking the folate binding site of the 
membrane-attached FR on the choroid epithelial 
cells. Oral folinic acid supplements led to nor-
mal CSF 5MTHF and partial or complete clinical 
recovery after 12 months. Serum FR autoimmu-
nity appears to represent an important factor in 
the pathogenesis of reduced folate transport to 
the nervous system among children with early-
onset low-functioning autism associated with or 
without neurological deﬁ cits. Early detection of 
FR autoantibodies may be a key factor in the pre-
vention and therapeutic intervention among this 
subgroup of patients with autism. 
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 The objective of the present study was to determine if children 
with early-onset low-functioning autism with or without neuro-
logical deﬁ cits have co-existing CFD and FR autoimmunity. 
 Patients and Methods 
 & 
 Patient population 
 The 25 patients selected for this study had early-onset low-func-
tioning autism associated with one or more of the major fea-
tures of the infantile-onset CFD syndrome: 1) marked unrest, 
irritability and insomnia during the ﬁ rst year of life; 2) decelera-
tion of head growth between 4 and 18 months; 3) psychomotor 
retardation followed by developmental arrest with or without 
regression; 4) hypotonia and ataxia presenting during the ﬁ rst 
two years; 5) pyramidal deﬁ cits starting in the lower limbs; 6) 
dyskinesias (choreoathetosis, ballism); and 7) epilepsy  [13,  15] . 
The diagnosis of infantile-onset low-functioning autism was 
established on the basis of the DSM-IV criteria with further 
assessment using the Autism Diagnostic Observation Schedule 
(ADOS) in conjunction with the Autism Diagnostic Interview 
(ADI) and the Vineland scales for children around 3 years 
 [10,  11,  18] . 
 In all children we ruled out infections during pregnancy, birth 
and neonatal injuries, hearing deﬁ cits, chromosomal disorders, 
defects of intracellular signalling as measured by abnormal 
platelet function, genetic abnormalities and inborn errors of 
metabolism, conditions known to be associated with secondary 
autism  [12,  16] . 
 All parents provided written informed consent for participation 
after the study had been approved by the University Hospital 
Aachen ethics committee. 
 Serum and CSF folate analysis 
 In all patients CSF was obtained according to a standardized pro-
tocol between 8:30 and 10:00 a.m. for analysis of 5-methyltet-
rahydrofolate, as described previously  [8] . The CSF results were 
compared with previously described values in 100 age-matched 
controls  [2,  4] . Serum folic acid, vitamin B12, homocysteine, and 
amino acids were determined in all patients. The serum folate 
was compared with the values obtained from age-matched 
healthy controls. 
 Serum and CSF assay of FR autoantibodies 
 For each patient and an age-matched healthy control, serum 
was collected for assay of FR autoantibodies of the blocking type. 
All identifying information was removed from the serum speci-
mens and they were identiﬁ ed only after the assays were com-
pleted and the results forwarded for analysis. 
 The procedure for identifying autoantibodies against FRs has 
been described previously  [17] 16). In brief, the patient ’ s serum 
was acidiﬁ ed, charcoal treated, neutralized and incubated over-
night with FR, puriﬁ ed from human placental membranes, fol-
lowed by adding [ 3 H] folic acid. Blocking autoantibodies, if 
present, prevent the binding of [ 3 H] folic acid that binds to the 
receptors in a 1:1  molar ratio. The amount of radioactivity bound 
to the receptors is inversely proportional to the titre of the block-
ing autoantibodies and is expressed as picomoles of [ 3 H] folic 
acid blocked from binding to the receptor per mL of the serum. 
 Available stored CSF samples were also assayed for blocking FR 
autoantibodies. 
 Analysis of FR1 and FR2 genes 
 The  FR1 gene maps to chromosome 11q13.3-q13. 5 and is com-
posed of seven exons spanning 6.7  kb, whereas the  FR2 gene is 
comprised of 5 exons and maps to the same chromosome locus 
at a distance of 23  kb from the  FR1 gene. PCR ampliﬁ cation of FR1 
and FR2 genes was performed on DNA isolated from whole blood 
using gene speciﬁ c primers spanning intron-exon boundaries. 
The PCR products of  ~ 250  bp each, were isolated and sequenced 
 [7] . 
 Treatment protocol 
 In patients with low 5MTHF levels in CSF, treatment consisted of 
oral supplementation with folinic acid starting at a dose of 
1.0  mg / kg / day  [13,  15] . Follow-up studies during treatment with 
folinic acid included repeated clinical assessment and EEG 
recordings. Clinical follow-up after folinic acid treatment 
included re-evaluation of the DSM-IV criteria, including the 
triad of social impairment, impaired communication and 
restricted behaviour with perseverative interests and activities. 
A lumbar puncture for measurement of 5MTHF was performed 
after 3 – 6 months following start of treatment. If CSF 5MTHF did 
not normalize, the dose of folinic acid was increased up to 2 –
 3  mg / kg / day, divided in two doses. All studies and investigations 
were performed after informed parental consent was obtained. 
 Results 
 & 
 Patient characteristics 
 Selection criteria for the twenty-ﬁ ve patients included 
early-onset low-functioning autism associated with at least 
one or more of the following seven major clinical criteria (see 
    Table 1 ) encountered in the infantile-onset CFD syndrome, 
i. e.: 1) marked unrest, irritability and insomnia in 22 patients; 
2) Deceleration of head growth in 11 patients; 3) psychomotor 
retardation and developmental arrest in 23 patients with regres-
sion in 1 patient, and cognitive decline in 1 patient (vide infra); 
2 patients (patients 1, 18) with Kanner syndrome had normal 
motor development; 4) hypotonia and ataxia in 20 patients; 5) 
distal pyramidal tract signs of the lower limbs in 9 patients; 6) 
dyskinesias in 9 patients (choreoathetosis in 5 and ballism in 4 
patients); and 7) epilepsy in 11 patients. 
 Four patients fulﬁ lled the criteria of infantile low-functioning 
autism (Kanner syndrome; patients 1, 18, 22, 24) associated with 
unrest, irritability and insomnia. Their history disclosed delayed 
acquisition of motor milestones in 2 of 4 patients (patients 22, 
24), and repeated neurological examination was normal. In 
twenty-one patients three or more of the above-mentioned 
major criteria were present and in two of these patients regres-
sion and cognitive decline occurred. In one patient (patient 12) 
the regression of mental and motor functions occurred after the 
age of 3.5 years leading to a severe neurological state manifest-
ing all major criteria of CFD. The other patient (patient 21) devel-
oped normally with mild speech delay until the age of 26 months 
when she developed acute lymphocytic leukaemia. A few 
months after starting chemotherapy, including methotrexate, 
she manifested cognitive decline and developed autism followed 
later by choreoathetosis, ataxia, and seizures. 
 Serum and CSF folate 
 Routine blood counts, serum vitamin B12, homocysteine and 
amino acids were within the normal range in all patients. Serum 
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folate levels in patients were normal and did not show statistical 
differences when compared to healthy controls (    Table 2 ). 
 The mean CSF concentration of 5MTHF was signiﬁ cantly 
decreased in all 25 patients with autism associated with or 
without neurological deﬁ cits (27.3  nmol / L compared to 82  nmol / L 
for healthy age-matched controls; see     Table 2 ). 
 Two patients had normal CSF folate values; one patient with 
macrocephaly (patient 1) fulﬁ lled all the criteria of infantile 
low-functioning autism (Kanner syndrome), while the other 
patient with normal head growth (patient 5) suffered from low-
functioning autism, marked motor delay and gait ataxia. Except 
for these two patients with normal folate values in their CSF, 23 
patients had CSF folate values well below the lowest value of the 
reference range of age-matched controls. Before folinic acid sub-
stitution, a follow-up lumbar puncture in 6 patients (patients 7, 
9, 16, 17, 22, 23) with low CSF folate showed a further decline of 
CSF 5MTHF values. 
 Autoantibodies against folate receptors 
 At the time of testing for serum autoantibodies against the folate 
receptor (FR) the mean age was 6.88. years (range from 2.8 to 
12.3 years). There were no statistical differences for age and gen-
der distribution between the patients and healthy controls (see 
    Table 2 ). The human FR antigen used in the autoantibody test-
ing was puriﬁ ed from human placental membranes. The two 
patients with normal CSF folate values, namely the patient with 
macrocephaly and Kanner syndrome (patient 1) and the patient 
with autism, motor delay and ataxia (patient 5), had no blocking 
FR autoantibodies. Four out of 23 patients (1 patient with Kan-
ner syndrome, i.e., patient 24; and 3 patients with low-IQ autism 
and neurological deﬁ cits, i.e., patients 4, 8, 14), who had low CSF 
folate levels, did not have FR autoantibodies in their serum. The 
results showed that 19 out of the 23 patients with low CSF 
5MTHF had autoantibodies of the blocking type against the 
human FR with a mean value of 1.05  pmol FR blocked / mL serum 
(range: 0.1 – 4.19). All 19 patients with low CSF folate and positive 
FR autoantibodies suffered from low-functioning autism and 
neurological deﬁ cits, except for the two patients with Kanner 
syndrome who were neurologically normal. All age-matched 
controls tested negative for FR autoantibodies. 
 In the patient with cognitive decline (patient 21), autism and 
signs of CFD followed a few months after chemotherapy for 
acute lymphocytic leukaemia, which included the antifolate 
drug methotrexate. The parents noticed cyclic phases during 
periods of 6 weeks after completion of chemotherapy, where 
aggression, loss of communicative skills and seizures alternated 
with phases where these signs were less manifest. During this 
period, weekly collection of serum for 6 weeks showed a nearly 
ﬁ ve-fold rise of FR autoantibodies from 1.2 up to a maximum 
titre at 9.2  pmol FR receptor blocked / mL serum. The increase in 
antibody titre was followed two weeks later by more incidences 
of aggressive behaviour, decreased communicative skills and 
more seizures at the time of maximum FR autoantibody levels 
(    Fig. 1 ). 
 Fig. 1  Changes in antibody titre and behavioural incidents over a period 
of six weeks in an 8.5-year-old girl with autism and neurological deﬁ cits 
(patient 21). The FR autoantibody titre rose from 1.2 to a maximum of 
9.2  pmoles FR blocked / mL serum during this period (-  -). The increase 
in autoantibody titre was followed by increased incidents of aggressive 
behaviour (- • -). 
 Table 2  Patient characteristics, laboratory values and statistical analysis 
 Analyte  Autism  Controls  Statistical Test  Signiﬁ cance 
 patient characteristics 
 male:female ratio  18:7  14:11  Fisher test  NS, p  =  0.1886 
 age (years)     
 – median  6.88  6.76  t-value  =  0.96  NS 
 – range  2.8 – 12.3  3.3 – 11.4   
 laboratory values 
 serum FR autoantibodies (pmoles / mL serum) 
 – number positive  19  0  Fisher test  p  <  0.0001 
 – mean Titre  1.05  0   
 – range  0.1 – 4.19    
 serum Folate (nM) 
 – mean  25.62  25.2  t-value  =  0.76  NS 
 – range  8.8 – 47  8.3 – 45   
 5MTHF in CSF (nM) 
 before treatment 
 – mean  27.3  82  t-value  =  7.77  P  <  0.001 
 – range  0 – 85.6  44 – 181   
 after folinic acid treatment 
 – mean  75.46  82  t-value  =  0.75  NS 
 – range  44.7 – 175  44 – 181   
 NS  =  not signiﬁ cant 
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 Serum FR autoantibodies determined on two occasions in 5 
other patients also showed minor or major titre ﬂ uctuations. In 
one patient with Kanner autism (patient 22), who had marked 
CSF folate ﬂ uctuations with subnormal values over the years, the 
low titre of FR autoantibodies had turned negative on follow-up, 
coinciding with normalization of CSF folate levels. One other 
patient (patient 17) who initially had no FR autoantibodies, 
developed autoantibodies with a titre of 3.18  pmol FR blocked /
 mL serum after 9 months. 
 In 5 patients with positive serum FR autoantibodies, where a 
stored CSF sample was available, FR autoantibodies were not 
detected in CSF. 
 Genetic analysis of FR1 and FR2 
 The coding exons of FR1 and FR2 genes showed normal sequences 
indicating that the low CSF folate could not be attributed to 
genetic errors of these genes. 
 Treatment and outcome 
 Two patients with low CSF folate received no treatment because 
of spontaneous disappearance of FR autoantibodies with nor-
malization of CSF folate in one (patient 22), and the other did not 
return for follow-up (patient 14). 
 Twenty-one patients with low CSF folate received treatment 
with high doses of N 5 -formyltetrahydrofolate (calcium folinate) 
at a dose of 1 – 3  mg / kg / day. The complete follow-up data for 3 
(patients 15, 18, 24) of the 21 patients who started treatment 
only recently, are not available yet and have not been included in 
the present study. In all 18 patients treated with calcium foli-
nate, CSF analysis showed normalization of 5MTHF levels 
(    Table 1 ). Two patients (patients 2, 4) who were diagnosed 
early and received treatment were cured with full recovery from 
autism and neurological deﬁ cits. In the whole group these two 
patients were among the youngest and were detected at 2 years 
8 months and at 3 years and 2 months. Three older patients 
(patients 11, 23, 25), diagnosed and treated from the age of 4.9, 8 
and 11.9 years, did not recover from autism but showed improve-
ment of their neurological deﬁ cits. The remaining thirteen 
patients in the age range of three and seven years showed a good 
response after treatment with improvement of most neurologi-
cal deﬁ cits, but only partial recovery from their autism. The par-
tial recovery in the latter group of 13 patients consisted of 
amelioration of social impairment in 4 of 13 patients, reversal of 
impaired communication in 9 of 13 patients and disappearance 
of perseverative behaviour and restricted interests in 6 of 13 
patients. The percentage of overall improvement and improve-
ment of each speciﬁ c feature plotted against the age at diagnosis 
and prior to treatment (    Fig. 2 ) showed a trend towards better 
outcome if the diagnosis and treatment are established at an 
earlier age. Although these are preliminary data, the curves also 
show that outcome of low-functioning autism with neurological 
deﬁ cits will be excellent if diagnosis is established before the 
age of three years. It also shows that treatment provided in this 
study has a positive effect on the alleviation of epilepsy, pyrami-
dal deﬁ cits and ataxia, but shows less response on irritability 
and a lack of effect on dyskinesias, mental retardation and 
autism with advancing age. 
 Discussion 
 & 
 Most patients of this study were selected on the basis of early-
onset low functioning autism associated with neurological deﬁ -
cits, while four patients did not manifest neurological deﬁ cits 
and could be classiﬁ ed as having Kanner syndrome. The inclu-
sion of neurological criteria was based upon previous ﬁ ndings in 
the infantile-onset CFD syndrome where 28 children with low 
CSF folate fulﬁ lled at least 3 or more of 7 major neurological cri-
teria  [13,  15] . Five of these 28 patients with CFD were found to 
have low-functioning autism associated with neurological deﬁ -
cits. In 4 of these 5 autistic children, FR autoantibodies were 
present in the serum, explaining the low CSF folate due to 
reduced folate transport across the choroid plexus  [15] . 
 With the exception of two, all 23 patients with low-functioning 
autism of the present study had low CSF folate accompanied by 
the presence of serum autoantibodies directed against FR in 19 
patients. Testing of CSF in 5 patients with positive serum FR 
autoantibodies, showed the absence of FR autoantibodies in 
their CSF, indicating that there is no intrathecal production or 
transfer of FR autoantibodies from blood. 
 The phenotype of most patients consisted of a combination of 
low-functioning autism and neurological deﬁ cits. However, 
three out of the four patients with the Kanner syndrome, also 
had low CSF folate and FR autoantibodies were present in two of 
these patients. In this context it should be stressed that within 
the classiﬁ cation of autism spectrum disorders the presence or 
absence of neurological deﬁ cits is often not mentioned or disre-
garded, particularly in the group of low-functioning infantile 
autism and atypical autism (PDD-NOS). Therefore, it remains 
unclear how frequently FR autoimmunity and CFD occur in 
autism without neurological deﬁ cits compared to autism associ-
ated with neurological abnormalities. For future studies, docu-
mentation and reporting of neurological abnormalities among 
patients with autism is imperative in order to correlate CFD and 
FR autoimmunity with either group. 
 Interestingly, repeated determination of serum FR autoantibod-
ies in one patient showed marked ﬂ uctuations in the titre that 
directly correlated with the severity of the clinical disease. This 
lends further support to the existence of an inverse correlation 
 Fig. 2  Response to therapy as indicated by improvement in neurological 
symptoms plotted against age at initial presentation and commencement 
of treatment. Following folinic acid administration for at least one year, a 
decrease in overall response to therapy with increasing age was observed. 
Improvement of mental retardation (-  -), autism (-  -), dyskinesias (-  -) 
and irritability (-  -) declines progressively if diagnosis and treatment are 
started at later ages, while pyramidal deﬁ cits (- • -), ataxia (-  -) show a 
better response throughout and are less affected by age. The hatched area 
represents the age at which treatment can reverse or substantially improve 
all of the neurological symptoms. 
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between the titre of FR autoantibodies with the transport and 
availability of folate to the brain. Fluctuations and the appear-
ance or disappearance of FR autoantibodies were also observed 
in 5 other patients. 
 Characterization of serum FR autoantibodies demonstrated the 
blocking properties of these autoantibodies with respect to 
folate binding by the human FR. A number of genetically deter-
mined factors are important in early programming and mainte-
nance of the immune system to avoid responses to the body ’ s 
own tissues and antigenic determinants  [3] . It may well be that 
in autism one or more genetic factors involved could disrupt tol-
erance against one ’ s own antigens leading to autoimmunity and 
interfere with the normal growth and developmental processes 
of the nervous system  [12,  16] . However, genetic factors that pre-
dispose to FR autoimmunity may provide a reasonable explana-
tion for the clinical phenotype as two of the youngest diagnosed 
and treated patients were cured from their autism following 
treatment with folinic acid. Screening of serum for FR autoanti-
bodies should be performed among infants and children mani-
festing autistic features and developmental delay, because early 
identiﬁ cation and intervention for these disorders appears to 
improve the prognosis and outcome. 
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